The AI in Business Podcast
Scaling AI for Clinical Trials - with Damion Nero of Takeda
May 7, 2025
Damion Nero, Head of Data Science at Takeda Pharmaceuticals, shares his expertise in applying AI and machine learning to drug development. He discusses how AI is revolutionizing clinical trials by streamlining tasks and enhancing patient engagement. Topics include the transformative potential of decentralized models and the integration of diverse data sources. Damion also highlights the ongoing challenges of trust and data integrity in healthcare, as well as the promise of future advancements in supply chain efficiency.
26:31
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- AI is revolutionizing clinical trials by enabling decentralized approaches that enhance patient interactions and streamline data processes.
- Addressing systemic challenges, such as trust issues and inconsistent data management, is crucial for the successful adoption of AI in drug development.
Deep dives
Decentralization and Remote Patient Engagement
AI is significantly advancing the decentralization of clinical trials by incorporating technologies such as chatbots and telehealth. This shift allows for improved remote patient interactions, thereby reducing the need for in-person visits, which many patients have avoided, especially since COVID-19. By streamlining various processes—like conducting consent forms and regular checkups—AI enhances efficiency in data collection, tracking, and analysis. Overall, these decentralized models aim to meet patient needs more swiftly and expand the number of drug candidates that can be brought to market.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
